We examined activity profiles of double-point modified analogues of vitamin D2.
The analogues were less toxic in vivo than 1,25D.
Pro-differentiating activities of analogues were stronger than that of 1,25D.
The analogues upregulated expression of CYP24A1 and CD14 stronger than 1,25D.
Neither calcemic, nor pro-differentiation effects were correlated to VDR binding.